Spectral Medical (EDT) Stock Overview
Focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
EDT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeSpectral Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.36 |
| 52 Week High | CA$1.84 |
| 52 Week Low | CA$0.77 |
| Beta | 0.17 |
| 1 Month Change | -2.86% |
| 3 Month Change | 4.62% |
| 1 Year Change | 56.32% |
| 3 Year Change | 423.08% |
| 5 Year Change | 183.33% |
| Change since IPO | -96.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| EDT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0.7% | 2.6% | 2.3% |
| 1Y | 56.3% | 29.9% | 34.5% |
Return vs Industry: EDT exceeded the Canadian Biotechs industry which returned 29.9% over the past year.
Return vs Market: EDT exceeded the Canadian Market which returned 34.5% over the past year.
Price Volatility
| EDT volatility | |
|---|---|
| EDT Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: EDT has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: EDT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 29 | Chris Seto | spectraldx.com |
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
Spectral Medical Inc. Fundamentals Summary
| EDT fundamental statistics | |
|---|---|
| Market cap | CA$410.79m |
| Earnings (TTM) | -CA$47.69m |
| Revenue (TTM) | CA$2.44m |
Is EDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDT income statement (TTM) | |
|---|---|
| Revenue | CA$2.44m |
| Cost of Revenue | CA$1.12m |
| Gross Profit | CA$1.33m |
| Other Expenses | CA$49.02m |
| Earnings | -CA$47.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 54.30% |
| Net Profit Margin | -1,952.87% |
| Debt/Equity Ratio | -30.4% |
How did EDT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 06:31 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spectral Medical Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Dean | ATB Cormark Historical (Cormark Securities) |
| Scott McAuley | Paradigm Capital, Inc. |
| Andre Uddin | Research Capital Corporation |